Collegeville, PA, United States of America

Sanjay Khandekar

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Sanjay Khandekar and His Contributions to Cancer Treatment

Introduction: Sanjay Khandekar, based in Collegeville, PA, has made significant strides in the field of cancer treatment through his innovative work. With a portfolio of three patents, Khandekar is dedicated to improving therapeutic approaches for patients suffering from diseases such as multiple myeloma.

Latest Patents: Khandekar's latest patents focus on advanced treatment methods for primary amyloidosis and cancer. His first patent involves a method for treating multiple myeloma through a combination of an anti-BCMA (B-cell maturation antigen) binding protein, such as an anti-BCMA antibody, alongside a proteasome inhibitor like bortezomib. This innovative combination may also integrate an anti-inflammatory compound, such as dexamethasone, to enhance therapeutic efficacy.

Another significant patent introduced by Khandekar details a treatment method combining an anti-BCMA antigen binding protein and an immunomodulatory drug like pomalidomide or lenalidomide, also potentially including dexamethasone. These cutting-edge approaches aim to improve outcomes for cancer patients.

Career Highlights: Sanjay Khandekar has been instrumental in pioneering new therapies at GlaxoSmithKline Intellectual Property Development Limited. His dedication to research and development is evident through his impactful patents, which reflect his expertise and commitment to advancing medical treatments.

Collaborations: Throughout his career, Khandekar has worked alongside notable colleagues such as Joanna Opalinska and Patrick A. Mayes. Their collaborative efforts have led to substantial advancements in cancer treatment methodologies and closing gaps in current healthcare approaches.

Conclusion: Sanjay Khandekar's contributions to the field of oncology through his innovative patents and collaborative spirit highlight his role as a key inventor in the medical arena. As research continues, his work at GlaxoSmithKline Intellectual Property Development Limited may pave the way for groundbreaking treatments that offer hope to patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…